Ar­row­head plots next steps for RNAi ther­a­pies af­ter mid-stage win in mixed hy­per­lipi­demia

Ar­row­head Phar­ma­ceu­ti­cals is mulling what’s next for a pair of RNA in­ter­fer­ence ther­a­pies af­ter re­port­ing pos­i­tive da­ta from sep­a­rate mid-stage tri­als in mixed hy­per­lipi­demia. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER